Edition:
United States

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

571.00GBp
2 Dec 2016
Change (% chg)

0.00p (+0.00%)
Prev Close
571.00p
Open
567.50p
Day's High
574.00p
Day's Low
565.00p
Volume
520,608
Avg. Vol
591,501
52-wk High
739.50p
52-wk Low
554.97p

Summary

Name Age Since Current Position

Garry Watts

59 2012 Non-Executive Chairman of the Board

Dame Pamela Louise Makin

54 2004 Chief Executive Officer, Executive Director

Rolf Soderstrom

2010 Chief Financial Officer, Executive Director

Melanie Lee

57 2014 Chief Scientific Officer

Paul Mussenden

2010 Company Secretary

Susan Foden

63 2015 Non-Executive Director

Graham Hetherington

56 2016 Non-Executive Director

Giles Kerr

2008 Senior Independent Non-Executive Director

Ian Much

2010 Independent Non-Executive Director

W. James O'Shea

2009 Independent Non-Executive Director

Richard Wohanka

2013 Independent Non-Executive Director

Andy Burrows

Director - Investor Relations

Biographies

Name Description

Garry Watts

Mr. Garry Watts, MBE, is Non-Executive Chairman of the Board of BTG Plc., since January 1, 2012. Garry is Chairman of Spire Healthcare and of The GADA® Group. He is the senior independent director of Stagecoach Group plc and a non-executive director of Coca-Cola Enterprises, Inc. Until December 2010, he was for seven years CEO of SSL International plc and before that CFO. Garry is a former partner at KPMG. He was previously an executive director of Celltech plc and of Medeva plc and a non-executive director of Protherics PLC. Other roles have included 17 years as a member of the UK Medicines and Healthcare Products Regulatory Agency Supervisory Board.

Dame Pamela Louise Makin

Dr. Dame Pamela Louise Makin, Ph.D. is Chief Executive Officer, Executive Director of BTG Plc. She joined BTG as Chief Executive Officer in October 2004 and she is a non-executive director of Premier Foods plc. From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998.

Rolf Soderstrom

Mr. Rolf B. Soderstrom is Chief Financial Officer, Executive Director of BTG Plc. He joined BTG as Chief Financial Officer in December 2008 from Protherics PLC, where he was Finance Director from August 2007. From 2004, he was a Divisional Finance Director of Cobham plc, managing a portfolio of businesses across Europe and the USA. From 2000 he was a Director of Corporate Finance at Cable & Wireless plc. Prior to this, he worked in the Corporate Recovery and Corporate Finance Department of PricewaterhouseCoopers after qualifying as a Chartered Accountant.

Melanie Lee

Dr. Melanie G. Lee, Ph.D., CBE, has been appointed as Chief Scientific Officer of BTG Plc, effective November 1, 2014. Melanie is the Chief Executive Officer of Syntaxin Limited, a Founder and director of the pharmaceutical consultancy Think10, and a non-executive director of H Lundbeck A/S. Melanie was previously the Chair of Cancer Research Technology and a Trustee and Deputy-Chair of Cancer Research UK. During her career Melanie has held a number of positions at Glaxo, GlaxoWellcome, Celltech and UCB. In 2008, Melanie was honoured with a CBE for her services to Medical Science.

Paul Mussenden

Susan Foden

Dr. Susan Foden, Ph.D., has been appointed as Non-Executive Director of the Company effective March 1, 2015. Susan has a background in the field of Biotech and Healthcare and holds a number of Non-Executive positions with both public and private companies. She is currently Chair of BerGenBio AS and Cizzle Biotech Ltd, holds non-executive roles with Vectura Group plc, Evgen Ltd, Source Bioscience plc and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund). Previously Susan has held the positions of Investor Director with the venture capital firm Merlin Biosciences, CEO of the technology transfer company, Cancer Research Campaign Technology Ltd and Head of Academic Liaison at Celltech Ltd. She studied Natural Sciences/Biochemistry and has an MA and DPhil from the University of Oxford.

Graham Hetherington

Mr. Graham Hetherington has been appointed as Non-Executive Director of the Company, effective 1 August, 2016. Graham has a broad range of international finance management and planning, audit, risk management and M&A experience. He was Chief Financial Officer of Shire plc from June 2008 to February 2014; Bacardi in 2007 and Allied Domecq plc from 1999 to 2005. He is a Fellow of the Chartered Institute of Management Accountants.

Giles Kerr

Mr. Giles F. B. Kerr is Senior Independent Non-Executive Director of BTG Plc. He joined BTG as a non-executive director in October 2007. Giles is currently the Director of Finance with the University of Oxford, UK. He is also a non-executive director of Victrex plc, Elan Corporation plc and Isis Innovation Ltd. Previously Giles was the Group Finance Director and Chief Financial Officer of Amersham plc, acquired by GE Healthcare in 2004. Prior to his role at Amersham, he was a partner with Arthur Andersen in the UK. He is a graduate of the University of York.

Ian Much

Mr. Ian F. R. Much is Independent Non-Executive Director of BTG Plc, since August 1, 2010. Ian is currently a non-executive director and the senior independent director of Chemring Group PLC and Senior plc. Ian was Chief Executive of De La Rue plc between 1998 and 2004 and Chief Executive of T&N plc between 1996 and 1998. Previous nonexecutive director appointments include Manchester United plc, Camelot plc and Admiral plc.

W. James O'Shea

Mr. W. James O'Shea is Independent Non-Executive Director of BTG Plc, since April 2009. He is a director of Zalicus Inc., Trevi Therapeutics, Inc. and MAP Pharmaceuticals, Inc. and a former Chairman of the US National Pharmaceuticals Council. From 2007 to 2008, he was Vice Chairman of Sepracor, Inc., where he was also President and Chief Operating Officer from 1999 to 2007. Previously Jim was Senior Vice President of Sales & Marketing and Medical Affairs for Zeneca Pharmaceuticals (US), a business unit of Zeneca Inc. While at Zeneca, he held several management positions of increasing responsibility in international sales and marketing in the US and the UK.

Richard Wohanka

Mr. Richard Wohanka has been appointed as Independent Non-Executive Director of BTG PLC., effective January 1, 2013. Previous experience Richard has more than 20 years’ experience in building asset management businesses. He was CEO of Union Bancaire Privée Asset Management between October 2009 and June 2012, and from 2001 to 2009 he was CEO of Fortis Investment Management.

Andy Burrows